MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Gotanda, Keisuke ^a   Hirota, Takeshi ^a   Matsumoto, Nozomi ^a   Ieiri, Ichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Fluorouracil; MicroRNAs; miR 433; Thymidylate synthase

Indexed keywords

FLUOROURACIL; LUCIFERASE; MICRORNA; MICRORNA 433; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; MESSENGER RNA; MIRN433 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TYMS GENE; WESTERN BLOTTING; APOPTOSIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; METABOLISM; TUMOR CELL CULTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; LUCIFERASES; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 84880947912     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-369     Document Type: Article

References (34)

1. Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD, Koropatnick J. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. J Pharmacol Exp Ther 2011, 338:952-963. 10.1124/jpet.111.183178, 21673071.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338. 10.1038/nrc1074, 12724731.
3. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995, 49:1419-1426. 10.1016/0006-2952(95)00067-A, 7763285.
4. Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Expression of thymidylatesynthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer 2011, 74:419-425. 10.1016/j.lungcan.2011.04.001, 21550686.
5. Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006, 95:607-615. 10.1038/sj.bjc.6603297, 2360692, 16880781.
6. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998, 82:1626-1631. 10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8, 9576280.
7. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 55:1407-1412.
8. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996, 77:441-451. 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N, 8630950.
9. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009, 101:1543-1552. 10.1093/jnci/djp328, 19841331.
10. Kline CL, Sheikh HS, Scicchitano A, Gingrich R, Beachler C, Finnberg NK, Liao J, Sivik J, El-Deiry WS. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther 2011, 12:557-568. 10.4161/cbt.12.7.18059, 21931273.
11. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2099-2105. 10.1200/JCO.2007.13.3934, 18445839.
12. Vignoli M, Nobili S, Napoli C, Putignano AL, Morganti M, Papi L, Valanzano R, Cianchi F, Tonelli F, Mazzei T, Mini E, Genuardi M. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. Pharmacol Res 2011, 64:242-248. 10.1016/j.phrs.2011.04.006, 21536130.
13. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20:191-197. 10.1247/csf.20.191, 7586009.
14. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000, 9:1381-1385.
15. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003, 63:2898-2904.
16. Afzal S, Gusella M, Jensen SA, Vainer B, Vogel U, Andersen JT, Brødbæk K, Petersen M, Jimenez-Solem E, Adleff V, Budai B, Hitre E, Láng I, Orosz E, Bertolaso L, Barile C, Padrini R, Kralovánszky J, Pasini F, Poulsen HE. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer [abstract]. Pharmacogenomics 2011, 12:1257-1267. 10.2217/pgs.11.83, 21919605.
17. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity [abstract]. Ther Drug Monit 2007, 29:190-196. 10.1097/FTD.0b013e318040b1fe, 17417073.
18. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis [abstract]. Pharmacogenet Genomics 2012, 22:290-304. 10.1097/FPC.0b013e328351875d, 22388795.
19. Fariña-Sarasqueta A, Gosens MJ, Moerland E, Van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Cell Oncol (Dordr) 2011, 34:327-335.
20. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854. 10.1016/0092-8674(93)90529-Y, 8252621.
21. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in Cancer. Cell 2009, 137:586-586.e1. 10.1016/j.cell.2009.04.040, 19410551.
22. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009, 9:293-302.
23. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, Pommier Y, Reinhold WC. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010, 9:1080-1091. 10.1158/1535-7163.MCT-09-0965, 2879615, 20442302.
24. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010, 285:21496-21507. 10.1074/jbc.M109.083337, 2898411, 20460378.
25. Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011, 585:402-408. 10.1016/j.febslet.2010.12.027, 21187093.
26. Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010, 103:1617-1626. 10.1038/sj.bjc.6605958, 2990590, 20978511.
27. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010, 9:2265-2275. 10.1158/1535-7163.MCT-10-0061, 20647341.
28. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004, 14:319-327. 10.1097/00008571-200405000-00007, 15115918.
29. Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977, 473:73-92.
30. Radparvar S, Houghton PJ, Houghton JA. Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys 1988, 260:342-350. 10.1016/0003-9861(88)90458-4, 3341747.
31. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997, 15:3223-3229.
32. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996, 14:176-182.
33. Luo H, Zhang H, Zhang Z, Zhang X, Ning B, Guo J, Nie N, Liu B, Wu X. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res 2009, 28:82. 10.1186/1756-9966-28-82, 2739520, 19531230.
34. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010, 11:136-146. 10.1016/S1470-2045(09)70343-2, 20022810.